Professional Documents
Culture Documents
"
# $%& '(! $ ))))& *+!
' $',& - '(! . (!
!/01232!04250
!
"
# $ $ % & '!
62 62 +
62 7 8 9
: ( 8 ;9
8 9
<8 9
# 7
0 !$ &
4'3 $ = &
> '3 $ &
! " 02. 1
- ? $<4<& :@
/ 0 A * B- * B
! $!1&: +C ( !
- 8< 9
- 6
- D0 E 2 . ? 1? F
$02. 1& 4. 4
-
dani
Biopsija limfnog
vora
oko 2 nedelje
UNAIDS
< 62 + G
62
@ G* H
I 62 + GB
@C :
*@H
C A @
@ @ :
G H "
J H $ @ +G&
62 A
62
-
CD4
CXCR4
CCR5
CCR5 CXCR-4
Q Y D M - NH2 T Y I S I G E M - NH2
S V DS
S N
Y
P
I Y DI
N Y Y T
T YD S MK
S D
E G E
IK Q GC
*
E E M GS
P Q F L N N C P
Q C S Q Y G S
ER
F C I E
V
N
I K
W D F G F
P Y
W
K
N
F
F S
S N
E * WY G
F
Y
P N DL W
V
V L
E F
E
K Q N H G E E N A N N F D A V L N
F A
Q A T S L K Q
Q R N F R D E F I T
IA A M S H Q F L F V L D R S Q F V
T N H
A
31- R
L
A
Y -89 102- Q
C C
T
Y S
R -168
L
K -197
T
N -258 A
Q
277-
D K
39- I
F
A
D -97 110- K *
C C Y V
I N -176
F
Q -202
S
D -262
K -282
W
P L H L T I L M Q PTL FA AV A HI IS IIS
P
Y S L
A
F PW
L
G L T
F
I G I
V
LG I
L
VI L
V YSI FPW VIH FFI VGM GII ATG
T T E I I T L T Y D
I P I L Y Y L
V F L T V
L
F Y L
S
P V L
L Y N
P M G
L F I V T L P F A
F I F L I G F A L P W A T T L FLV L N L L G P W L F
VGI SYS PLA IIV FCA CCH
G F F F V L F C H D L
VG F D L G S V V A M V F L C G A V L F N L
S I
C V I
Y N I G N S V I L VIW C S L A P
M N A I F F T
I W
I V P L L L G Y I L I
L L I Y M I I I V L H F A Y V I C I L Y
MLV RY I V II TVT FLA
I L N L I S V G S T I Y
L V L T I F F A L S V
L I Y I L T V L L I G Y -65 75- K K -239 308- A G
I E VG D -133 154- K 224- S
K
N -57 A QH
67- I D -125 146- V 219- K R -235 E
303- K Q D R K L
C D R G T V
F L L V Cytoplasmic K T LY
A L A F S A
Y F L A Y F L S K T L
K T R N F K M K
L T L R L R S A L T
R
L K S
M
V R H Q K
H R
S S G RS V S
A
F R
K A I H K I SK K L
T C R VH R G H Q K
V R N C G KR
P
V R E K K K ATN SQR I K G
Acidic H A A
F Q Q E A
L S G Ser/Thr
V F A L K C
C S I
H rich
P S S S ES S
F ET VS
Basic T
S R T
Y R
E = Predicted G-protein binding domains H S
G V S S A S S -352
E
CCR5 = CXCR4 Q
E I S
V G L - COOH
352
! !
" # " #
7 , ? , ?K ?
=
, L
$
! % % ) *+ ,
! &' ! ! - ./
! 0
( ! $
!
4. G 4P4'G 44'@
) % 1+ ! 1+ 0(
I M 50 B/ B+ NOJN : B
1 62
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
+ 4. G
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
! +
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
+ 44'@
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
! G
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
3 =
Copyright © 2002-2008 Pfizer Inc. All rights reserved. Reprinted with permission.
Q2 ,(242!/> 1 2'> 10
Reverzna
Integracija morfogeneza
transkripcija
Integraza
adsorpcija Reverzna
Transkriptaza
CCR5
Maturacija
Proteaza
CXCR4
HIV integracija
- ./ 2 3 3 %
•
8 9
- ./ ( ( 0
:RR ; B B
4 ( 0! ,! - ./ ( % 5%
< 62
Humani virusi imunodeficijencije (HIV) poti u od sli nih virusa majmuna
(Simian Immunodeficiency viruses – SIV)
62 12 62 + 12
• < $ &
= $ &
• 3
• < ,
4 62
• 0 . (!
• < =
• 1
• 2
' 4. G
62
• 87 , 9
• / 62
• 0 +
0 +
=
Tk1
V4 (CTL epitope) Neutralization
CD4 binding site V3 epitope
T1
C3
V5
C4
Penetration
Fusion
C2
C1
T2
V1
NH2 V2
Outside
Inside
Hypervariable region
Less variable region
COOH Conserved region
V1, V2, V3, V4, V5 Variable regions
CPE C1, C2, C3, C4 Conserved regions
6 ( 3 - ./ 0
. 4. G%, ? 7 =
6 ,=
0 8 ? 9 = B
< 8 9
CD4 T
2 $ BBBB&
!
BBBBBBBB CD8 T
CD4 T cell
DC
HIV specific
CD4 T
< 62 -
62 4. G% , ?
- ./ 17 8
& &% , 9 & + ,
9 && 1+
9 & &% , % 0
+ ,
:% !
0 +
&,
doma in
virus elija
imunski odgovor
1 " =
62 prenošenja
1. Seksualnim kontaktom
heteroseksualno
homoseksualno
1-12
1-12weeks
nedelja 8-10 years 1-2 years
!
62
6-10
6-10 godina
years 1-2 years
1 62 -
62 $02. 1&
1-2 godine
< 62
simptomi simptomi
HIV viremija
0 1 2 3 4 5 6 / 2 4 6 8 10
1°infekcija nedelje godine
vreme
0
). 7
•
•
=, % ,
=
"> =7#'
",, #6 >
% , ", 7#T
% "> ? #T
6 00',
• ,, ! ",,.# U 7 0%
• % , " 7 #I
)). 7
I $I3 & @ ! %
( $( <& /
6. . $. / &
V1 W$1X & . % ! A % ! @' $', & ) %
V( $(3 & / 0
V2 W$2. & 9 %
V0 W"> 6/#> ( !
V/ WR "B6/$ #C
A.
7 & "A ! #
62
> ,! !, D 7
7 !
D! !
7 ! 6
D , )C
. (
7
. 03
5 0% ,
.
% 6 3
. 7 Inhibitori
integraze
0 $0' &
$+ @&
4K ,+
0
..4 J,4 ./ ' '
0K4 ,3 ,
( < I
(',2 (3 ! 0, 7
((',2
1X 6 # .'
3 0<
<2
32 ', ,<
0<
2
2.
'@ 2
K 6 00', + + @B 1T
Targets for ending the AIDS epidemic
1T - 6 2 R02. 1
* H
* H
* H
))Y
6 , :
, 2 22
$<,/ 2 22&
( #
• / ,= - <,/ 2$6 ,/ 2&
• / ,= - <,/ 22$6 ,/ 22&
, :
2(
V 6 ,/ 2 J ! 5" 0
0
V 6 ,/ 220 0 I 2(
6 ,/